PDF-Scientific and Regulatory Considerations
Author : lois-ondreau | Published Date : 2016-06-15
1 for Bioequivalence BE of Dry Powder Inhalers DPIs Sau Larry Lee PhD Science StaffImmediate Office Office of Generic Drugs 2011 GPhAFDA Fall Technical Conference October
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Scientific and Regulatory Considerations" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Scientific and Regulatory Considerations: Transcript
1 for Bioequivalence BE of Dry Powder Inhalers DPIs Sau Larry Lee PhD Science StaffImmediate Office Office of Generic Drugs 2011 GPhAFDA Fall Technical Conference October 4 2011 This pres. 4. Objectives. To Understand:. Advertising & Well-Being. Ethical Campaign Development. Role of Government Agencies. Self-Regulation. Regulation of IBP Techniques. Is Advertising Full of Double Standards?. the Financial Services Bill. . 19 March 2012 . The Senate Room, Senate House, . University of London. Professor Kern Alexander, . Chair for Law and Finance . University of Zürich and . Senior Research Fellow, Centre for Financial Analysis and Policy. Version 1.0 dated June 2010. These slides are available at: . www.dtf.vic.gov.au/betterregulation. . Questions to: . betterregulationunit@dtf.vic.gov.au. . Victorian Regulatory Change Measurement (RCM). Mark . Atalla. , . PharmD. Disclosure. I have no relevant financial relationships with commercial interests pertaining to the content presented in this program. Objectives. 3. Key Things to Walk Away With:. . GMP- A Regulatory Perspective. Regulatory Perspective in entering . Global . Pharma. Markets. Regulatory Perspective in entering . Global . Pharma. Markets. World wide market of . pharma. products:. Recent Trends and Insurance Considerations. March 2015. www.pwc.com. – . 2. March 2015. Cyber Risk. – Recent Trends and Insurance Considerations . Cyber Risk – Recent Trends and Insurance Considerations . Elaine Chao. Secretary of Transportation. On Tuesday, the full Senate considered, and voted to confirm, the nomination of Elaine Chao to be the 18th Secretary of Transportation. Secretary Chao’s nomination was agreed to by a vote of 93 to 6, with her husband Majority Leader Mitch McConnell (R-KY) abstaining from voting. Of additional note, the 6 nay votes were not in opposition to Secretary Chao, who has enjoyed widespread and overwhelming support from the Senate, but were protest votes in opposition to President Trump’s travel ban executive order.. Hypothesis, Theory, and law . How science really works. Objective. : Students will be able to explain what a scientific law and theory are and give examples of each.. Essential Question:. What are the differences between a scientific law and theory?. products. Milan . Smid. . Prequalification team . Principal objective of PQP capacity building: . To facilitate availability of quality priority medicines. Good quality submissions and compliance with "good practices". Jim Corkill . | Controller. Business and Financial Services Controller’s Office. Stewardship. Stewardship. The careful and responsible management of something entrusted to one’s care.. Fund Accounting. Regulatory Control Training Workshop. Regulatory Cooperation Forum. Peter Hughes. 6-10 November, 2017. Morocco. Learning Objectives. After going through this presentation the participants are expected to be familiar with:. Investigational New Drug Application (IND); Summary of regulations and guidelines . Introduction of . cGMP's. /principles of validation . Introduction to QA/QC principles . Good Laboratory Practice (GLP) compliance . time-resolved Resonant Inelastic X-ray Scattering. Figure(s) . short figure caption or label. What is to be measured?. What processes, properties etc. will be probed. Why is this information important?. of. human . challenge trials. Nele Berthels. FAMHP Vaccine Symposium. , . BRUSSELS, . 9 September 2017. Disclaimer. This presentation . reflects . my . personal point of . view, . and . not necessarily the .
Download Document
Here is the link to download the presentation.
"Scientific and Regulatory Considerations"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents